Background
Little is known about inflammation/immune activation during pregnancy in people with HIV (PWH) and growth in their children who are HIV-exposed and uninfected (CHEU).
Methods
Using data from the Pediatric HIV/AIDS Cohort Study and an HIV-seronegative comparison group, we assessed associations of: (1) HIV status, mode of HIV acquisition [perinatally-acquired vs. non-perinatally-acquired], and type of antiretroviral therapy (ART) with inflammation/immune activation in pregnancy; (2) inflammation/immune activation in pregnancy with growth (weight-for-age, length-for-age, and weight-for-length Z-score) of CHEU at 12 months. Interleukin(IL)-6, high-sensitivity C-reactive protein(hs-CRP), soluble(s) TNF-alpha receptor 1&2(sTNFR1, sTNFR2), sCD14, and sCD163 were measured between 13-27 weeks’ gestation. Linear regression models were fit to estimate differences between groups for each log-transformed biomarker, adjusted for confounders.
Results
188 pregnant PWH (39 perinatally-acquired, 149 non-perinatally-acquired) and 76 HIV-seronegative persons were included. PWH had higher IL-6, sTNFR1, sCD14, and sCD163 and lower sTNFR2, compared to HIV-seronegative persons in adjusted models. Among PWH, sCD163 was higher in those with perinatally-acquired vs. non-perinatally-acquired and on PI-based vs. INSTI-based ART. Higher maternal concentrations of IL-6, sTNFR2, and hs-CRP were associated with poorer growth at 12 months.
Conclusions
Maternal HIV status is associated with a distinct profile of inflammation/immune activation during pregnancy, which may influence child growth.